Emerging retatrutide, a dual -action drug targeting equally GLP-1 and GIP receptors, is creating considerable excitement within the weight loss community. Preliminary clinical trials have shown impressive losses in physical weight and improvements in physiological markers for people with overweight. Experts believe this novel approach may signif… Read More